Generic EpiPen Cleared By FDA As Teva Challenges Mylan
Actavis CEO: Teva-Mylan deal could be "value-destroying" - גלובס
Teva makes $40B offer for Mylan
Mylan board rejects Teva takeover bid
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Big blow for Teva as FDA approves Mylan's generic Copaxone - Globes
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Mylan Raises Offer for Perrigo Again and Is Rejected Again - The New York Times
$40B deal: Teva offers to buy Mylan
Generic drugmaker Teva makes $40bn offer for rival Mylan
Teva's Copaxone holds its own in wake of Mylan's generic price cut | Fierce Pharma
Teva makes $40 billion offer for Mylan
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
Mylan surprises analysts, Teva with long-delayed Copaxone approvals | Fierce Pharma
Mylan shares soar after takeover proposal
Mylan NDEA contamination prompts Teva recall in US
Teva Issues New Letter to Mylan NV Confirming Seriousness Of Offer To Acquire Mylan - Jewish Business News
Mylan Rejects Teva Takeover Bid As Too Low | Mint
Teva drops bid for Mylan, buys Allergan's generics unit | Pittsburgh Post-Gazette
The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Mylan Should Try Teva On for Size - WSJ
